Exploration of the Activation Mechanism of the Epigenetic Regulator MLL3: A QM/MM Study.


Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
17 07 2021
Historique:
received: 05 06 2021
revised: 07 07 2021
accepted: 10 07 2021
entrez: 6 8 2021
pubmed: 7 8 2021
medline: 7 10 2021
Statut: epublish

Résumé

The mixed lineage leukemia 3 or MLL3 is the enzyme in charge of the writing of an epigenetic mark through the methylation of lysine 4 from the N-terminal domain of histone 3 and its deregulation has been related to several cancer lines. An interesting feature of this enzyme comes from its regulation mechanism, which involves its binding to an activating dimer before it can be catalytically functional. Once the trimer is formed, the reaction mechanism proceeds through the deprotonation of the lysine followed by the methyl-transfer reaction. Here we present a detailed exploration of the activation mechanism through a QM/MM approach focusing on both steps of the reaction, aiming to provide new insights into the deprotonation process and the role of the catalytic machinery in the methyl-transfer reaction. Our finding suggests that the source of the activation mechanism comes from conformational restriction mediated by the formation of a network of salt-bridges between MLL3 and one of the activating subunits, which restricts and stabilizes the positioning of several residues relevant for the catalysis. New insights into the deprotonation mechanism of lysine are provided, identifying a valine residue as crucial in the positioning of the water molecule in charge of the process. Finally, a tyrosine residue was found to assist the methyl transfer from SAM to the target lysine.

Identifiants

pubmed: 34356675
pii: biom11071051
doi: 10.3390/biom11071051
pmc: PMC8301819
pii:
doi:

Substances chimiques

ASH2L protein, human 0
DNA-Binding Proteins 0
KMT2C protein, human 0
Nuclear Proteins 0
Protons 0
RBBP5 protein, human 0
Transcription Factors 0
Tyrosine 42HK56048U
Lysine K3Z4F929H6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Fondo Nacional de Desarrollo Científico, Tecnológico y de Innovación Tecnológica
ID : 1181082

Références

Biochemistry. 2013 Oct 1;52(39):6866-78
pubmed: 24000826
Genet Mol Res. 2014 Sep 12;13(3):7513-8
pubmed: 25222251
Nature. 2011 Jul 27;476(7360):298-303
pubmed: 21796119
J Chem Theory Comput. 2011 Mar 8;7(3):625-632
pubmed: 21516178
J Comput Chem. 2010 Jun;31(8):1707-14
pubmed: 20082388
J Am Chem Soc. 2018 Mar 28;140(12):4327-4334
pubmed: 29460630
Nat Rev Mol Cell Biol. 2013 Dec;14(12):819-29
pubmed: 24150612
J Chem Theory Comput. 2014 Sep 9;10(9):3745-3756
pubmed: 25221443
Nat Struct Biol. 2003 Jul;10(7):545-52
pubmed: 12819771
Nature. 2013 Oct 17;502(7471):333-339
pubmed: 24132290
Biochemistry. 2007 Dec 25;46(51):14838-44
pubmed: 18044969
J Chem Theory Comput. 2011 Feb 8;7(2):525-37
pubmed: 26596171
Nature. 2010 Jan 21;463(7279):360-3
pubmed: 20054297
Pathol Oncol Res. 2011 Jun;17(2):429-33
pubmed: 21116761
PLoS One. 2010 Jan 11;5(1):e8570
pubmed: 20084102
Biochim Biophys Acta. 2014 Dec;1846(2):366-79
pubmed: 25123655
Proc Natl Acad Sci U S A. 2007 May 22;104(21):8797-802
pubmed: 17517655
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
J Comput Chem. 2004 Aug;25(11):1400-15
pubmed: 15185334
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20659-64
pubmed: 19088188
J Am Chem Soc. 2005 Oct 5;127(39):13643-55
pubmed: 16190730
Phys Rev B Condens Matter. 1988 Jan 15;37(2):785-789
pubmed: 9944570
J Comput Chem. 2006 Nov 30;27(15):1787-99
pubmed: 16955487
Cancer Cell. 2014 May 12;25(5):652-65
pubmed: 24794707
Proc Natl Acad Sci U S A. 2009 May 26;106(21):8513-8
pubmed: 19433796
J Comput Chem. 2004 Sep;25(12):1463-73
pubmed: 15224390
J Comput Chem. 2005 Dec;26(16):1781-802
pubmed: 16222654
Nature. 2016 Feb 25;530(7591):447-52
pubmed: 26886794
J Phys Chem B. 1998 Apr 30;102(18):3586-616
pubmed: 24889800
J Chem Phys. 2010 Apr 21;132(15):154104
pubmed: 20423165
Trends Biochem Sci. 2002 Aug;27(8):396-402
pubmed: 12151224
Cell. 2002 Oct 4;111(1):91-103
pubmed: 12372303
J Am Chem Soc. 2006 Feb 1;128(4):1272-8
pubmed: 16433545
EMBO J. 2003 Jan 15;22(2):292-303
pubmed: 12514135
J Chem Phys. 2008 Jan 7;128(1):014106
pubmed: 18190184
J Am Chem Soc. 2010 May 12;132(18):6498-506
pubmed: 20394428
J Chem Phys. 2010 Oct 7;133(13):134105
pubmed: 20942521
Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5728-32
pubmed: 18391193
Science. 2011 Jan 28;331(6016):435-9
pubmed: 21163964

Auteurs

Sebastián Miranda-Rojas (S)

Departamento de Ciencias Químicas, Facultad de Ciencias Exactas, Universidad Andres Bello, República 275, Santiago 8370146, Chile.

Kevin Blanco-Esperguez (K)

Departamento de Ciencias Químicas, Facultad de Ciencias Exactas, Universidad Andres Bello, República 275, Santiago 8370146, Chile.

Iñaki Tuñón (I)

Departamento de Química Física, Universidad de Valencia, 46100 Burjasot, Spain.

Johannes Kästner (J)

Institut für Theoretische Chemie, Universität Stuttgart, Pfaffenwaldring 55, 70569 Stuttgart, Germany.

Fernando Mendizábal (F)

Departamento de Química, Facultad de Ciencias, Universidad de Chile, P.O. Box 653, Las Palmeras 3425, Ñuñoa, Santiago 7800003, Chile.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH